Production of stable isotopes utilizing the plasma separation process

A plasma separation process (PSP) is being operated at Theragenics Corporation's (R), Oak Ridge, TN, facility for the enrichment of stable isotopes. The PSP utilizes ion cyclotron mass discrimination to separate isotopes on a relatively large scale. With a few exceptions, nearly any metallic element could be processed with PSP. Output isotope enrichment factor depends on natural abundance and mass separation and can be fairly high in some cases. The Theragenics (TM) PSP facility is believed to be the only such process currently in operation. This system was developed and formerly operated under the US Department of Energy Advanced Isotope Separation program. Theragenic (TM) also has a laboratory at the PSP site capable of harvesting the isotopes from the process and a mass spectrometer system for analyzing enrichment and product purity. Since becoming operational in 2002, Theragenics (TM) has utilized the PSP to separate isotopes of several elements including: dysprosium, erbium, gadolinium, molybdenum and nickel. Currently, Theragenics (TM) is using the PSP for the separation of Pd-102, which is used as precursor for the production of 103(Pd). The Pd-103 radioisotope is the active ingredient in TheraSeed (R), which is used in the treatment of early stage prostate cancer and being investigated for other medical applications. New industrial, medical and research applications are being investigated for isotopes that can be enriched on the PSP. Pre-enrichment of accelerator or reactor targets offers improved radioisotope production. Theragenics operates 14 cyclotrons for proton activation and has access to HFIR at ORNL for neutron activation of radioisotopes. (c) 2005 Elsevier B.V. All rights reserved.